This Article Full Text Full Text (PDF) Supplementary Data Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oberthuer, A. Articles by Fischer, M. Search for Related Content PubMed PubMed Citation Articles by Oberthuer, A. Articles by Fischer, M. Social Bookmarking                            What's this?

Customized Oligonucleotide Microarray Gene Expression–Based Classification of Neuroblastoma Patients Outperforms Current Clinical Risk Stratification

André Oberthuer, Frank Berthold, Patrick Warnat, Barbara Hero, Yvonne Kahlert, Rüdiger Spitz, Karen Ernestus, Rainer König, Stefan Haas, Roland Eils, Manfred Schwab, Benedikt Brors, Frank Westermann, Matthias Fischer

From the Department of Pediatric Oncology and Hematology, Children's Hospital; the Center for Molecular Medicine; Department of Pathology, University of Cologne, Cologne; Departments of Tumor Genetics (B030) and Theoretical Bioinformatics (B080), German Cancer Research Center, Heidelberg; Max-Planck-Institute for Molecular Genetics, Berlin, Germany

Address reprint requests to André Oberthuer, MD, Children's Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Kerpener Strasse 62, D-50924 Cologne, Germany; e-mail: andre.oberthuer{at}uk-koeln.de

Purpose To develop a gene expression–based classifier for neuroblastoma patients that reliably predicts courses of the disease.

Patients and Methods Two hundred fifty-one neuroblastoma specimens were analyzed using a customized oligonucleotide microarray comprising 10,163 probes for transcripts with differential expression in clinical subgroups of the disease. Subsequently, the prediction analysis for microarrays (PAM) was applied to a first set of patients with maximally divergent clinical courses (n = 77). The classification accuracy was estimated by a complete 10-times-repeated 10-fold cross validation, and a 144-gene predictor was constructed from this set. This classifier's predictive power was evaluated in an independent second set (n = 174) by comparing results of the gene expression–based classification with those of risk stratification systems of current trials from Germany, Japan, and the United States.

Results The first set of patients was accurately predicted by PAM (cross-validated accuracy, 99%). Within the second set, the PAM classifier significantly separated cohorts with distinct courses (3-year event-free survival [EFS] 0.86 ± 0.03 [favorable; n = 115] v 0.52 ± 0.07 [unfavorable; n = 59] and 3-year overall survival 0.99 ± 0.01 v 0.84 ± 0.05; both P < .0001) and separated risk groups of current neuroblastoma trials into subgroups with divergent outcome (NB2004: low-risk 3-year EFS 0.86 ± 0.04 v 0.25 ± 0.15, P < .0001; intermediate-risk 1.00 v 0.57 ± 0.19, P = .018; high-risk 0.81 ± 0.10 v 0.56 ± 0.08, P = .06). In a multivariate Cox regression model, the PAM predictor classified patients of the second set more accurately than risk stratification of current trials from Germany, Japan, and the United States (P < .001; hazard ratio, 4.756 [95% CI, 2.544 to 8.893]).

Conclusion Integration of gene expression–based class prediction of neuroblastoma patients may improve risk estimation of current neuroblastoma trials.

Supported by the Deutsche Krebshilfe (Grant No. 50-2719), the Bundesministerium für Bildung und Forschung through the National Genome Research Network 2 (NGFN2 Grants No. 01GS0456 and 01GR0450), the Competence Network Pediatric Oncology and Hematology, and the Fördergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.

B.B., F.W., and M.F. contributed equally to this work.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. De Preter, J. Vermeulen, B. Brors, O. Delattre, A. Eggert, M. Fischer, I. Janoueix-Lerosey, C. Lavarino, J. M. Maris, J. Mora, et al. Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature Clin. Cancer Res., March 1, 2010; 16(5): 1532 - 1541. [Abstract] [Full Text] [PDF]

				J. Loven, N. Zinin, T. Wahlstrom, I. Muller, P. Brodin, E. Fredlund, U. Ribacke, A. Pivarcsi, S. Pahlman, and M. Henriksson MYCN-regulated microRNAs repress estrogen receptor-{alpha} (ESR1) expression and neuronal differentiation in human neuroblastoma PNAS, January 26, 2010; 107(4): 1553 - 1558. [Abstract] [Full Text] [PDF]

				K. De Preter, S. De Brouwer, T. Van Maerken, F. Pattyn, A. Schramm, A. Eggert, J. Vandesompele, and F. Speleman Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds Clin. Cancer Res., June 1, 2009; 15(11): 3690 - 3696. [Abstract] [Full Text] [PDF]

				I. Oehme, H. E. Deubzer, D. Wegener, D. Pickert, J.-P. Linke, B. Hero, A. Kopp-Schneider, F. Westermann, S. M. Ulrich, A. von Deimling, et al. Histone Deacetylase 8 in Neuroblastoma Tumorigenesis Clin. Cancer Res., January 1, 2009; 15(1): 91 - 99. [Abstract] [Full Text] [PDF]

				A. Oberthuer, L. Kaderali, Y. Kahlert, B. Hero, F. Westermann, F. Berthold, B. Brors, R. Eils, and M. Fischer Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR Clin. Cancer Res., October 15, 2008; 14(20): 6590 - 6601. [Abstract] [Full Text] [PDF]

				E. Fredlund, M. Ringner, J. M. Maris, and S. Pahlman High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma PNAS, September 16, 2008; 105(37): 14094 - 14099. [Abstract] [Full Text] [PDF]

				S. Bilke, Q.-R. Chen, J. S. Wei, and J. Khan Whole Chromosome Alterations Predict Survival in High-Risk Neuroblastoma without MYCN Amplification Clin. Cancer Res., September 1, 2008; 14(17): 5540 - 5547. [Abstract] [Full Text] [PDF]

				B. Hero, T. Simon, R. Spitz, K. Ernestus, A. K. Gnekow, H.-G. Scheel-Walter, D. Schwabe, F. H. Schilling, G. Benz-Bohm, and F. Berthold Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97 J. Clin. Oncol., March 20, 2008; 26(9): 1504 - 1510. [Abstract] [Full Text] [PDF]

				H. Voth, A. Oberthuer, T. Simon, Y. Kahlert, F. Berthold, and M. Fischer Identification of DEIN, a Novel Gene with High Expression Levels in Stage IVS Neuroblastoma Mol. Cancer Res., December 1, 2007; 5(12): 1276 - 1284. [Abstract] [Full Text] [PDF]